ArticleSkin health and disease2024
Effect of tumour necrotic factor-α, interleukin-17 and interleukin-22 on the expression of filaggerin-2 and hornerin: Analysis of a three-dimensional psoriatic skin model.
Article in Skin health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Skin organoids: an emerging platform from three-dimensional construction to regenerative application].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Review
- The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation.Allergy · 2026Article
- Effect of tumour necrotic factor-α, interleukin-17 and interleukin-22 on the expression of filaggerin-2 and hornerin: Analysis of a three-dimensional psoriatic skin model.Skin health and disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Filaggrin-2 (FLG2) and hornerin (HRNR) are members of the S100 fused-type protein family, which share many properties with filaggrin (FLG). A previous study demonstrated that the expression of FLG2 was significantly decreased in psoriatic skin relative to that in normal skin. In contrast, the HRNR expression in psoriatic skin varied among studies. Objectives: We aimed to investigate the effect of tumour necrosis factor-α (TNF-α), IL-17A and IL-22 on the expression of FLG2 and HRNR using a three-dimensional psoriatic skin model. Methods: In the present study, we generated a 3D psoriatic skin model that was stimulated with TNF-α, IL-17A and IL-22 for 3D skin equivalents. Using this model, we examined the altered expression of FLG2 and HRNR by quantitative reverse transcription polymerase chain reaction and immunostaining. Results: In the 3D psoriatic skin model, the expression of FLG2 and HRNR was significantly reduced compared with that in the 3D control skin. FLG2 expression was significantly decreased by stimulation with TNF-α, IL-17A and IL-22. In contrast, the expression of HRNR was markedly increased by stimulation with IL-22, although it was slightly decreased by TNF-α or IL-17A compared to the 3D control skin. Conclusion: TNF-α, IL-17A and IL-22 have different effects on FLG2 and HRNR expression and epidermal structure formation. Furthermore, FLG2 and HRNR may play different roles in barrier formation and the pathogenesis of psoriasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.